Although blood is considered one of the most promising fluid biomarker candidates for AD, this approach still has to overcome critical issues, such as low concentrations (e.g. p-tau: ~ pg/ml)8, plasma stability, blood–brain barrier penetration of key protein biomarkers to be used for primary diagnosis and prognosis. This evidence concerns the gene MAPT and Alzheimer disease.